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compared to AAV vector transduction following other administration 
routes in mice. AAV serotype 2 (AAV2) was used to deliver a 
self-complementary CMV-GFP reporter cassette via intrastromal, 
intracameral, intravitreal, subretinal, or suprachoroidal injections. 
These injections were validated by fundoscopy and optical coherence 
tomography at the time of injection. Transduction was assessed six 
weeks later by fundoscopy and whole globes were evaluated for 
histology. Transduction of the stroma, ciliary body, retinal ganglion 
cells, outer retina, and retinal pigment epithelium could be seen in the 
various routes of delivery to the eye. In particular, the transduction of 
multiple retinal layers throughout the retina without the damage of 
retinal detachment and widespread distribution makes suprachoroidal 
injections a better delivery route than to subretinal injection.
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An excessive amount of empty capsids are generated during regular 
AAV vector production process. These pseudo-vectors often remain 
in final vectors used for animal studies or clinical trials. The potential 
effects of these pseudo-vectors on AAV transduction have been a 
major concern. In the current study, we systemically examined how 
the AAV pseudo-vectors interact with the full AAV vectors in the 
transduction processes. Three different types of AAV pseudo-vectors 
were used: syngeneic AAV pseudo-vector (sAAV, purified from the 
full AAV vector preparation with the same reporter gene), null AAV 
pseudo-vector (nAAV, produced by using AAV packaging plasmid 
and adenoviral helper plasmid), and allogeneic AAV pseudo-vector 
(aAAV, purified from the AAV vector preparation with a genome 
different to reporter gene). All three AAV2 pseudo-vectors exhibited 
inhibition effects on full AAV2 vectors particle transduction in a dose 
dependent manner in vitro. AAV2 pseudo-vectors not only inhibited 
full AAV2 vector transduction but also decreased gene expression 
from full AAV8 vectors. However, sAAV2 pseudo-vectors exhibited 
less inhibition effects on the transduction efficiency of full AAV2 or 
AAV8 vectors compared with nAAV2 or aAAV2 pseudo-vectors in 
vitro. In contrast, all three kinds of AAV8 pseudo-vectors did not show 
such inhibition effects on full AAV8 and AAV2 vectors in vitro or in 
vivo. Moreover, the sAAV8 pseudo-vector enhanced its full AAV8 
vector transduction while nAAV8 and aAAV8 pseudo-vector did 
not have similar effects. Nine fold sAAV8 pseudo-vectors increased 
AAV8-TTR-hF8-X5 transduction by 2~5-fold in two different 
hemophilia A mouse models as measured the coagulation activity 
of factor VIII by aPTT assays and antigen levels by Elisa. Further 
characterization showed that sAAV8 and aAAV8 pseudo-vectors 
contain DNAs of varying sizes. In general, these DNAs still have 
AAV ITR sequences and partial vector genomes near ITRs. It is likely 
that such partial genome could anneal to the full AAV genomes and 
facilitate the second strand DNA synthesis thus increasing full AAV 
transduction.
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Introduction: Gene therapy offers long term solutions for chronic 
diseases, whereby the transgene is continuously expressed upon single 
vector administration. However in some cases it would be desirable 
to tightly regulate or switch off transgene expression. Methods: We 
are investigating regulated gene expression based on the mifepristone 
(MFP)-inducible GeneSwitch system. The GeneSwitch protein 
comprises yeast Gal4 DNA-binding domain, a human p65 activation 
domain and a MFP controlled domain derived from the human 
progesterone receptor. The classical GeneSwitch system consists 
of two expression cassettes on two separate vectors; one containing 
the GeneSwitch sequence and one containing the transgene. We 
compared this two-vector system to a single-vector system, where 
the two cassettes were put into one vector for efficacy in vitro and in 
vivo. Results: We show inducible expression of EPO, IGF and GNDF 
obtained in vitro upon addition of MFP to cells transfected with 
plasmids containing GeneSwitch and the gene expression cassette. 
The kinetics of EPO mRNA and protein expression followed a dose 
dependent fashion in the range of 0.1 to 10 nM MFP and reached a 
plateau at higher MFP concentrations. Surprisingly, the GeneSwitch 
protein expression decreased 48h after MFP induction. The indicibility 
of the single versus the two-vector system of GeneSwitch-EPO 
was compared. Both systems were equally inducible based on 
total amount of EPO produced in the presence of MFP and related 
to background expression in the absence of MFP. In vivo proof of 
concept was obtained for EPO in the liver. EPO is characterized 
by clear expression kinetics in plasma and raises blood hematocrit, 
hence provides a reliable in-life read-out for gene inducibility. Mice 
were injected with different doses of AAV5-AAT-GeneSwitch-EPO 
and gene expression was induced in two separate rounds at 4 and 8 
weeks p.i. EPO plasma levels increased approximately 2-logs in the 
single or two-vector system-injected mice, compared to un-induced 
groups. Moreover in the absence of MFP background expression of 
EPO was lower in the single-vector system and hematocrit levels 
were unaffected. Measurements of MFP in tissue matrices and in 
plasma by mass spectrometry show the presence of MFP in plasma 
and liver, validating applicability of the GeneSwitch system in the 
liver. Conclusion: Overall, our data indicate that transgene expression 
can be repeatedly regulated in the liver using the GeneSwitch system 
and provides us with a novel AAV5 vector for further development.
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Despite having the best safety profile of any current clinical viral 
vector, it is known that AAV preps contain contaminating sequences 
that are packaged alongside the expression cassette at a low rate. 
These sequences can originate from production plasmid DNA, or 
chromosomal DNA from producer cell lines. It has been reported 
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that sequences from the expression cassette producer plasmid are 
more likely to be packaged into AAV than DNA from other producer 
plasmids, or chromosomal DNA. We hypothesised that in the 
expression cassette plasmid, backbone sequences directly fl anking 
the ITRs might be packaged into AAV at a higher rate than sequences 
further away from either ITR. We fi rst confi rmed the presence of 
these sequences via PCR amplifi cation of non-expression cassette 
DNA fl anking the ITR sequence up to 1.5kb in length in an AAV 
prep. Sequential qPCR assays showed that plasmid sequences at a 
range of distances up to 2kb from the ITR make up between 1% and 
9% of AAV particles. Most signifi cantly, there was an observable 
decreasing trend in contaminant titer as distance from the ITR 
increased. Contaminant sequences closer to the ITRs (within 1kb) 
are detected at a 100 fold greater rate than distal plasmid DNA (9kb 
from ITRs on the same plasmid). The disparity in the levels of ITR 
adjacent DNA sequences, compared to sequences 9kb from either ITR, 
suggest that the origin of this DNA is from within AAV particles rather 
than residual plasmid DNA remaining after purifi cation procedures. 
ITR adjacent contamination is present at both a TRS mutated ITR 
(required for self-complementary vectors) and non TRS mutated 
ITRs. Contaminating plasmid sequences were present when the 
transgene was half of the packaging capacity (2.3kb FIX prep) and 
at the full capacity (5kb FVIII prep) at comparable levels, suggesting 
that increasing the transgene size with stuffer DNA to create a full 
genome will not solve this issue. Previous studies have concluded that 
increasing the size of the backbone with stuffer DNA reduces the level 
of plasmid backbone contamination, as the two ITRs are then not in 
range of each other to facilitate reverse packaging. However, the total 
plasmid size in our studies was >20kb. Therefore, the ITRs should not 
be in range for this to occur. We hypothesise that these ITR adjacent 
sequences are either a product of read-through from the expression 
cassette into fl anking sequences, due to ineffi cient cleavage at the ITR 
breakpoint, or from reverse priming mediated by only 1 functional 
ITR. In the current expression cassette plasmids examined, the Kanr 
gene and bacterial f1origin of replication are within the range of the 
fl anking sequences that could be packaged. With current, unsolved 
clinical challenges for AAV, including transaminitis post high dose 
infection, it is clear that clinical AAV vectors should be designed to 
contain as little contamination as possible. We conclude that newly 
designed AAV production plasmids should contain signifi cant lengths 
of stuffer DNA fl anking each ITR (at least 2kb) to ensure that bacterial 
sequences are not packaged into AAV preps. Further research into 
vector design is required to eliminate this source of non-functional 
DNA from AAV produced for the clinic.
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Our initial observation of the selective tropism of AAV3 serotype 
vectors for human liver cancer cell lines and primary human 
hepatocytes (Mol Genet Metabol., 98: 289-299, 2009; Hum Gene 
Ther., 21: 1741-1747, 2010; Gene Ther., 19: 375-84, 2012), led 
to renewed interest in this serotype, since AAV3 vectors and their 
variants have recently proven to be extremely effi cient in targeting 
human and non-human primate hepatocytes in vitro as well as in vivo 
(Nature, 506: 382-386, 2014; Hum Gene Ther., 25: 1023-1034, 2014; 
Mol Ther., 23: 1867-1876, 2015; Mol Ther., 23: 1877-1887, 2015). 
Our previous studies also documented that the combined use of AAV3 
ITRs, AAV3 Rep proteins, and AAV3 capsids led to the production 
of recombinant AAV3 vectors with higher titers than those produced 
using AAV2 ITRs, AAV2 Rep proteins, and AAV3 capsids. We also 
observed that the transduction effi ciency of Rep3/ITR3 AAV3 vectors 
was ~4-fold higher than that of Rep2/ITR2 AAV3 vectors in a human 
hepatocellular carcinoma (HCC) cell line, Huh7, under identical 
conditions. In the present studies, we extended these observations 
to include capsid-optimized AAV3 vectors in which two surface-
exposed residues (Serine 663 and Threonine 492) were mutated to 
generate a S663V+T492V double-mutant vector to examine whether 
the transduction effi ciency of the Rep3/ITR3-S663V+T492V-AAV3 
vectors could be further augmented. To this end, two human HCC 
cell lines, Huh7 and LH86, were transduced with WT-AAV3 and 
S663V+T492V-AAV3 vectors generated with ITR2/Rep2 and ITR3/
Rep3, respectively, under identical conditions. Consistent with our 
previously published studies, the transduction effi ciency of the 
S663V+T492V-AAV3 vectors was ~10-fold higher than its WT 
counterpart, and interestingly, there was a further 2-fold increase in 
the transduction effi ciency of both vectors generated with ITR3/Rep3, 
compared with those generated with ITR2/Rep2 (Fig. 1A). We next 
evaluated the transduction effi ciency of these vectors in a murine 
xenograft model bearing human liver tumors. AAV3-EGFP-Neo 
vectors generated with either ITR2/Rep2, or with ITR3/Rep3, were 
injected intra-tumorally at a dose of 1x1011 vgs/tumor. Forty-eight hrs 
post-vector administrations, transgene expression was determined in 
each tumor by Western blot assays. These results indicated that AAV3 
vectors generated with ITR3/Rep3 transduced human liver tumors in 
vivo ~2-fold more effi ciently than those generated with ITR2/Rep2 
(Fig. 1B). It is anticipated that the combined use of ITR3/Rep3, and 
S663V+T492V-AAV3 capsids will further increase the transduction 
effi ciency of these vectors. Taken together, our data suggest the 
transduction effi ciency of AAV3 vectors can be signifi cantly improved 
both by using homologous Rep proteins and ITRs as well as by capsid-
optimization. The use of these modifi ed AAV3 vectors should prove 
useful in liver-directed human gene therapy.
